Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Ratios

Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2025)

Vanda Pharmaceuticals' Capital Leases history spans 2 years, with the latest figure at $4.1 million for Q4 2025.

On a quarterly basis, Capital Leases rose 29.56% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 29.56% increase, with the full-year FY2025 number at $4.1 million, up 29.56% from a year prior.
Capital Leases hit $4.1 million in Q4 2025 for Vanda Pharmaceuticals, up from $2.8 million in the prior quarter.
Over the last five years, Capital Leases for VNDA hit a ceiling of $4.1 million in Q4 2025 and a floor of $2.8 million in Q3 2025.